Announcements
Sidley Represents Exiger in Its Acquisition of XSB
August 9, 2024
Sidley represented Exiger in its acquisition of logistics intelligence platform XSB, a data science company known for its artificial intelligence (AI)-based applications that transform data into actionable intelligence. Exiger is a market-leading supply chain and third-party risk AI company. The acquisition will enhance Exiger’s AI offerings for customers in the logistics, PEO, and acquisition industries.
The Sidley team was led by partner Grace Jamgochian, managing associate Flora G. Gonzalez, and associate Chloe Marks (M&A and Private Equity), and included Howard J. Stanislawski (Global Arbitration, Trade and Advocacy); Ash Nagdev and Sasha Hondagneu-Messner (Privacy and Cybersecurity); Ernesto R. Claeyssen (Commercial Litigation); E. Kyle Barnett and Ida Ebeid (Technology and Life Sciences Transactions); James Heyworth (Securities and Shareholder Litigation); Eric S. Wolf and Gregory C. Matisoff (Employee Benefits and Executive Compensation); Eric G. Hoffman (Labor, Employment and Immigration); Christian Brause and Eric M. Grosshandler (Tax); and Vadim Brusser (Antitrust and Competition).
The Sidley team was led by partner Grace Jamgochian, managing associate Flora G. Gonzalez, and associate Chloe Marks (M&A and Private Equity), and included Howard J. Stanislawski (Global Arbitration, Trade and Advocacy); Ash Nagdev and Sasha Hondagneu-Messner (Privacy and Cybersecurity); Ernesto R. Claeyssen (Commercial Litigation); E. Kyle Barnett and Ida Ebeid (Technology and Life Sciences Transactions); James Heyworth (Securities and Shareholder Litigation); Eric S. Wolf and Gregory C. Matisoff (Employee Benefits and Executive Compensation); Eric G. Hoffman (Labor, Employment and Immigration); Christian Brause and Eric M. Grosshandler (Tax); and Vadim Brusser (Antitrust and Competition).
連絡先


得意分野
Suggested News & Insights
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private PlacementJuly 17, 2026Sidley Finishes H1 2026 Among Top Three US$1B+ Dealmakers in TexasJuly 16, 2026European Commission Signals Targeted Procedural Simplification of the Foreign Subsidies Regulation – Without Weakening EnforcementJuly 16, 2026Inspection Rights, Internal Affairs, and Personal Jurisdiction: Orchid Global’s Procedural LessonJuly 15, 2026Sidley Advises EMZ Partners on Its Significant Minority Investment in Steinbach & VollmannJuly 13, 2026Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZenecaJuly 13, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


